Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Bangladesh Pharmaceutical Market 2020-2025 - Share of Generic Drugs Expected to Surpass 85% by 2025, Favoring Local Pharma Companies

Research and Markets Logo

News provided by

Research and Markets

Jul 23, 2020, 14:45 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, July 23, 2020 /PRNewswire/ -- The "Bangladesh Pharmaceutical Market Future Opportunity Outlook 2025" report has been added to ResearchAndMarkets.com's offering.

Report Highlights

  • Bangladesh Pharmaceutical Market Opportunity: More Than US$ 6 Billion by 2025
  • Share Of Local Pharmaceutical Companies: >90%
  • Share of Generics Drugs in Pharmaceutical Market: >75%
  • Leading Drugs Market Insight by Availability, Dosage & Price Analysis
  • Number of Ongoing Clinical Studies: > 300 Clinical Studies
  • Pharmaceutical Exports Opportunity: > US$ 450 Million by 2025

Biotech pioneers of the Bangladesh Pharmaceutical industry are considered as a valuable tool for the overall improvement and efficacy of the market. To a surprise, Bangladesh pharmaceutical market had been largely dependent on the imports as well as on multinational companies for meeting the needs of the local population. However, in recent times local pharmaceutical companies have emerged as the game-changer by contributing more than 90% of the overall available medicines in the market.

The pharmaceutical market has been witnessing excellent growth in recent years and is expected to surpass US$ 6 Billion by 2025 with an absolute growth of 114% from 2019 levels. Majority of this growth will be contributed by local companies with a market share of more than 90% as similar to past trends attained over the last two decades.

The notable change that attracted the world towards the country's market status is the consequence of innovation in science and research and development sector. This has surprisingly transformed the curve of the overall ratio or contribution of Bangladesh pharmaceutical market at the global level. In a short period of time, the breed of biotechnology firm settled in Bangladesh has accumulated certain practices and has qualified itself to bring down the unmet needs and solutions to numerous patient population. Rise in life expectancy, growing per capita income, changing disease profile, population growth, lifestyle changes and growing patient population are some of the key drivers are that are booming the consumption of local market.

The pioneering impressive export work achieved by the country is the repercussion of the novel biomolecular techniques that have been implemented in the clinical trial platform. The initiatives led by the researchers towards developing a pharmaceutical market have boosted the research and development productivity as well as benefitted the stakeholders and the patients they serve. At present, the total count of the country with respect to clinical trials is more than 300. Bangladesh based pharmaceutical companies have raised their significant amount of clinical trials to advance level. The capital raised by the biotech companies and the research centers has been supported widely by public and private sectors, government bodies and the regulatory bodies.

Being abundant in pharmaceutical-based human resources is formulating the market towards several development programs. Although the country has been competing powerfully with the other emerged markets of the world but digital stringency, which been a transforming source for the other markets is on the move in Bangladesh at a very slow pace. It is important for the Bangladesh pharmaceutical market to interact with dominating markets to improve their platforms for drug discovery and development sector in order to strike with the pharmaceutical market of the US and Europe.

In upcoming years, the government of Bangladesh will play a major role in the rapid growth of the pharmaceutical market by providing favorable policies for easy drug approval, production and marketing of new products. Government is focusing to reduce the dependence of Bangladesh over the import of raw material and establishment of API Park will act as a turning point for this purpose. The top 50 companies are setting their facilities at the active pharmaceuticals ingredient industrial park that will help in the production of patented and already opened active pharmaceuticals ingredients. It is expected that the development of API Park will complete by the next 2 years, which will reduce the expenditure related to the import of raw material.

All the associated factors are in favor for the rapid growth Bangladesh pharmaceutical market and it is expected to grow with a CAGR of more than 12% during 2019-2025 period. The share of generic drugs is expected to surpass 85% by the 2025, which will further strengthen the dominance of local pharmaceutical companies in the market. In addition to this, the presence of leading multinational pharmaceutical companies is also increasing in Bangladesh, which is indicating towards the competitive landscape in upcoming years.

Key Topics Covered

1. Introduction to Bangladesh Pharmaceutical Market
1.1 Overview
1.2 Current Market Scenario

2. Bangladesh - Cancer Prevalence & Statistics
2.1 Overview
2.2 By Gender
2.3 By Age
2.4 By Leading Cancer Type
2.4.1 Oesophagus Cancer
2.4.2 Lip,Oral Cavity Cancer
2.4.3 Breast Cancer
2.4.4 Lung Cancer
2.4.5 Cervix Uteri Cancer

3. Bangladesh - Diabetes Prevalence & Statistics
3.1 By Population
3.2 By Diabetes Type
3.2.1 Type 1 Diabetes
3.2.2 Type 2 Diabetes
3.3 By Age & Gender
3.4 Obesity & Overweight

4. Bangladesh HIV Infection - Prevalence & Statistics

5. Bacterial & Viral Infections in Bangladesh - Prevalence& Statistics
5.1 Hepatitis-B
5.2 Diarrheal Disease
5.3 Tuberculosis
5.4 Pneumonia & Influenza

6. Cardiovascular Diseases in Bangladesh - Prevalence & Statistics
6.1 Hypertension
6.2 Coronary Heart Disease & Stroke

7. Bangladesh Pharmaceutical Market Segmentation
7.1 By Product - Generics & Patented Drugs
7.2 By Treatment System
7.3 By Local & Multinational Companies
7.4 By Therapeutic Class
7.5 By Trade - Import & Export Market

8. Bangladesh Pharmaceutical Market Leading Drugs Insight - Availability, Dosage & Price Analysis
8.1 Seclo (Omeprazole)
8.2 Sergel (Esomeprazole)
8.3 Maxpro (Esomeprazole)
8.4 Pantonix (Pantoprazole)
8.5 CEF-3 (Cefixime Trihydrate)
8.6 Mixtard 30 (Insulin Human & Isophane Insulin Human)
8.7 Napa Extra (Paracetamol & Caffeine)
8.8 Losectil (Omeprazole)
8.9 Napa (Paracetamol)
8.10 Exium (Esomeprazole)

9. Bangladesh Pharmaceutical Market - Clinical Trials Insight
9.1 By Phase
9.2 By Recruiting Status
9.3 By Indication

10. Bangladesh Pharmaceutical Market Dynamics
10.1 Drivers for Bangladesh Pharmaceutical Market
10.2 Challenges for Bangladesh Pharmaceutical Market

11. Bangladesh Pharmaceutical Market Future Outlook

12. Competitive Landscape
12.1 Local Companies
12.1.1 Square Pharmaceuticals
12.1.2 Incepta Pharma
12.1.3 Beximco Pharma
12.1.4 Opsonin Pharma
12.1.5 Ranata Limited
12.1.6 Beacon Pharmaceuticals
12.1.7 Chemist Laboratories
12.1.8 Central Pharmaceuticals
12.1.9 Delta Pharma
12.1.10 Everest Pharmaceuticals
12.1.11 Desh pharmaceuticals
12.1.12 Decent Pharmaceuticals
12.1.13 FNF Pharmaceuticals
12.2 Multinational Companies
12.2.1 Amgen
12.2.2 Eli - Lilly
12.2.3 Merck
12.2.4 Pfizer
12.2.5 GlaxoSmithKline
12.2.6 Roche
12.2.7 AstraZeneca
12.2.8 Genentech
12.2.9 Sanofi
12.2.10 Novo Nordisk

For more information about this report visit https://www.researchandmarkets.com/r/nzulhh

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.